These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10686309)

  • 1. Nephrotoxicity of calcineurin inhibitors: new therapeutic approaches.
    Abramowicz D; Wissing KM; Broeders N
    Transplant Proc; 2000 Feb; 32(1A Suppl):3S-5S. PubMed ID: 10686309
    [No Abstract]   [Full Text] [Related]  

  • 2. Methods and outcomes of calcineurin inhibitor reduction or withdrawal in patients with chronic allograft nephropathy after the first year posttransplantation.
    Weir MR
    Transplant Proc; 2001 Jun; 33(4 Suppl):19S-28S. PubMed ID: 11406264
    [No Abstract]   [Full Text] [Related]  

  • 3. Mycophenolate mofetil, along with ATG and cyclosporine, significantly lowers the incidence of acute rejection episodes in renal transplant recipients.
    Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Iñigo V; Manresa JM; Masramón J
    Transplant Proc; 1999 Sep; 31(6):2259-60. PubMed ID: 10500567
    [No Abstract]   [Full Text] [Related]  

  • 4. MMF-based regimen in maintenance therapy after kidney transplantation.
    Wu MJ; Shu KH; Cheng CH; Chen CH; Lian JD
    Transplant Proc; 2000 Nov; 32(7):1748-50. PubMed ID: 11119918
    [No Abstract]   [Full Text] [Related]  

  • 5. Case 2: strategies to minimize the use of calcineurin inhibitors (CNIs).
    Hariharan S
    Transplantation; 2002 Sep; 74(5):746-7. PubMed ID: 12357988
    [No Abstract]   [Full Text] [Related]  

  • 6. Mycophenolate mofetil in cyclosporine-associated nephrotoxicity.
    Ducloux D; Fournier V; Bresson-Vautrin C; Rebibou JM; Saint-Hillier Y; Chalopin JM
    Transplant Proc; 1998 Sep; 30(6):2825-7. PubMed ID: 9745583
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of mycophenolate mofetil in patients with chronic cyclosporine nephrotoxicity.
    Wombolt DG; McCune TR; Stewart M
    Transplant Proc; 1998 Jun; 30(4):1194. PubMed ID: 9636483
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined sirolimus-calcineurin inhibitor immunosuppressive therapy in simultaneous heart and kidney transplantation: a retrospective analysis of a single hospital's experience.
    Hsu KH; Chou NK; Tsai MK; Chi NH; Chen YS; Yu HY; Wang CH; Ko WJ; Tsao CI; Lee PH; Wang SS
    Transplant Proc; 2010 Apr; 42(3):934-7. PubMed ID: 20430208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replacement of calcineurin inhibitors by mycophenolate mofetil: effect on hemoglobine levels.
    Suwelack B; Kobelt V; Hillebrand U; Gerhardt U; Matzkies F; Hohage H
    Transplant Proc; 2002 Aug; 34(5):1808-9. PubMed ID: 12176585
    [No Abstract]   [Full Text] [Related]  

  • 10. Lymphocyte subsets in renal transplant recipients treated with mycophenolate mofetil.
    François M; Büchler M; Halimi JM; Al-Najjar A; Valentin JF; Thibault G; Lebranchu Y
    Transplant Proc; 2000 Dec; 32(8):2781-2. PubMed ID: 11134803
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug regimens affect cadaveric kidney graft survival.
    Kauffman HM; Cherikh WS; Delmonico FL
    Transplant Proc; 2001; 33(1-2):1029-30. PubMed ID: 11267176
    [No Abstract]   [Full Text] [Related]  

  • 12. Mycophenolate mofetil overlap in liver transplant recipients with chronic cyclosporine nephrotoxicity.
    Torras J; Figueras J; Lama C; Fabregat J; Ramos E; Rafecas A; Gil-Vernet S; Pares D; Busquets J; Jaurrieta E
    Transplant Proc; 1999 Sep; 31(6):2430. PubMed ID: 10500656
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of various immunosuppressive regimes in second renal transplants.
    Toronyi E; Remport A; Járay J; Máthé Z; Borka P; Perner F
    Transplant Proc; 2001 May; 33(3):2315-6. PubMed ID: 11377543
    [No Abstract]   [Full Text] [Related]  

  • 14. Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice.
    Vathsala A; Lu YM
    Transplant Proc; 2001; 33(7-8):3137-9. PubMed ID: 11750348
    [No Abstract]   [Full Text] [Related]  

  • 15. Mycophenolate mofetil versus azathioprine in simultaneous pancreas-kidney transplant recipients on cyclosporine.
    Fabrega AJ; Corwin CL; Hunsicker L
    Transplant Proc; 1998 Jun; 30(4):1562-3. PubMed ID: 9636634
    [No Abstract]   [Full Text] [Related]  

  • 16. Mycophenolate mofetil, ATG, and cyclosporine in the induction treatment of renal transplant recipients minimizes the incidence of acute rejection episodes.
    Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Marcas LI; Manresa JM; Masramón J
    Transplant Proc; 1998 Aug; 30(5):2226-7. PubMed ID: 9723449
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of different immunosuppression on the outcome of pediatric renal transplants.
    García Meseguer C; Alonso A; Vanegas JJ; Martinez Débora MJ; Navarro M
    Transplant Proc; 1999 Sep; 31(6):2280. PubMed ID: 10500577
    [No Abstract]   [Full Text] [Related]  

  • 18. Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria.
    Morales J; Fierro A; Benavente D; Zehnder C; Ferrario M; Contreras L; Herzog C; Buckel E
    Transplant Proc; 2007 Apr; 39(3):591-3. PubMed ID: 17445551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is cyclosporine toxic to the transplanted kidney with acute tubular necrosis?
    Ritz M; Pascoe MD; Pontin AR; Kahn D
    Transplant Proc; 1998 Jun; 30(4):1204. PubMed ID: 9636488
    [No Abstract]   [Full Text] [Related]  

  • 20. Individualization of immunosuppressive therapy. II. Sirolimus as a less nephrotoxic alternative to calcineurin inhibitors.
    Lisik W; Kahan BD
    Transplant Proc; 2006; 38(1):69-73. PubMed ID: 16504667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.